NJ-LARSEN-&-TOUBRO-INFOT
2.11.2022 20:46:36 CET | Business Wire | Press release
Fosfor, the Data Products Unit of Larsen & Toubro Infotech (BSE: 540005, NSE: LTI), today announced that it has been approved as a Snowflake Ready Technology Validation Partner. Achieving this validation confirms Fosfor’s DataOps product, Spectra, and Decision Intelligence product, Lumin, adhere to Snowflake’s best practices around performance, reliability, and security.
Under the Snowflake Ready Technology Validation program, Snowflake audits and validates a company’s native integration with Snowflake based on functional and performance best practices. The audit requires a native connector that has been available for at least six months, as well as a set of joint customers and case studies. With this validation, Fosfor joins a list of prominent product companies that have been approved under this program.
“Efficient access to quality data helps organizations quickly inform strategies and decisions – it is a must-have for our customers," says Tarik Dwiek, Head of Technology Alliances at Snowflake. “Fosfor’s take on monetizing data at speed and scale for enterprises complements Snowflake's commitment to capitalizing on the infinite potential of the Data Cloud and creates a winning proposition for our customers.”
Along with LTI recently being awarded Elite tier partner status and receiving the Delivery Partner of the Year award at the 2022 Snowflake Summit, the Technology Ready designation further reinforces the long-standing partnership between the companies. A growing number of Fosfor customers are realizing the synergistic value created by combining Fosfor’s data and AI capabilities with Snowflake’s Data Cloud.
“The Snowflake-Fosfor partnership is a natural fit in exploding value from Data & AI for enterprises globally and is creating immense value for our joint customers with Fosfor products’ seamless native connectivity to Snowflake. Fosfor products like Spectra are solving major DataOps challenges for enterprises, while Lumin converts data into decision insights with ease for business users,” said Satyakam Mohanty, Chief Product Officer, Fosfor. "We are delighted to be in lockstep with Snowflake to strengthen our valued partnership and in our aligned vision to create limitless business impact for enterprises.”
Snowflake has been a key partner of LTI since 2018, and of the Fosfor product suite since its launch in December of 2021. Click here to learn more about the powerful combination of Fosfor and Snowflake.
About Fosfor
The Fosfor Product Suite is the only end-to-end suite for optimizing all aspects of the data-to-decisions lifecycle. Fosfor helps you make better decisions, ensuring you have the right data in more hands in the fastest time possible. The Fosfor Product Suite comprises of Spectra, a comprehensive DataOps platform; Aspect, a no-code unstructured data processing platform; Optic, a data fabric to facilitate data discovery-to-consumption journeys; Refract, a data science and MLOps platform; and Lumin, a decision intelligence platform. Collectively, the Fosfor suite helps businesses discover the hidden value in their data. The Fosfor Data Products Unit is part of LTI, a global technology consulting and digital solutions company with hundreds of clients and operations in 33 countries. For more information, visit www.fosfor.com.
About LTI:
LTI (NSE: LTI) is a global technology consulting and digital solutions company helping more than 500 clients succeed in a converging world. With operations in 33 countries, we go the extra mile to assist our clients and accelerate their digital transformation journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivalled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 50,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees, and shareholders. Learn more at http://www.lntinfotech.com or follow us at @LTI_Global.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102005946/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom